Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/2490
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Heyer, E. E. | en |
dc.contributor.author | Mercer, T. R. | en |
dc.contributor.author | Barbaric, D. | en |
dc.contributor.author | Marshall, G. M. | en |
dc.contributor.author | MacKenzie, K. L. | en |
dc.contributor.author | Trahair, T. | en |
dc.contributor.author | Gifford, A. J. | en |
dc.contributor.author | Fordham, A. | en |
dc.contributor.author | Mayoh, C. | en |
dc.contributor.author | Fadia, M. | en |
dc.contributor.author | Lukeis, R. | en |
dc.contributor.author | Wood, A. C. | en |
dc.contributor.author | Valvi, S. | en |
dc.contributor.author | Walker, R. D. | en |
dc.contributor.author | Blackburn, J. | en |
dc.date.accessioned | 2022-11-07T23:32:05Z | - |
dc.date.available | 2022-11-07T23:32:05Z | - |
dc.date.issued | 2019 | en |
dc.identifier.citation | 3 , 2019, p. 1-11 | en |
dc.identifier.other | RIS | en |
dc.identifier.uri | http://dora.health.qld.gov.au/qldresearchjspui/handle/1/2490 | - |
dc.description.abstract | PURPOSE Before anaplastic lymphoma kinase (ALK) inhibitors, treatment options for ALK-positive inflammatory myofibroblastic tumors (AP-IMTs) were unsatisfactory. We retrospectively analyzed the outcome of patients with AP-IMT treated with crizotinib to document response, toxicity, survival, and features associated with relapse. METHODS The cohort comprised eight patients with AP-IMT treated with crizotinib and surgery. Outcome measures were progression-free and overall survival after commencing crizotinib, treatment-related toxicities, features associated with relapse, outcome after relapse, and outcome after ceasing crizotinib. RESULTS The median follow-up after commencing crizotinib was 3 years (range, 0.9 to 5.5 years). The major toxicity was neutropenia. All patients responded to crizotinib. Five were able to discontinue therapy without recurrence (median treatment duration, 1 year; range, 0.2 to 3.0 years); one continues on crizotinib. Two critically ill patients with initial complete response experienced relapse while on therapy. Both harbored RANBP2-ALK fusions and responded to alternative ALK inhibitors; one ultimately died as a result of progressive disease, whereas the other remains alive on treatment. Progression-free and overall survival since commencement of crizotinib is 0.75 6 0.15% and 0.83 6 0.15%, respectively. CONCLUSION We confirm acceptable toxicity and excellent disease control in patients with AP-IMT treated with crizotinib, which may be ceased without recurrence in most. Relapses occurred in two of three patients with RANBP2-ALK translocated IMT, which suggests that such patients require additional therapy.L20025174742019-08-14 <br />2019-08-16 <br /> | en |
dc.language.iso | en | en |
dc.relation.ispartof | JCO Precision Oncology | en |
dc.title | Crizotinib and surgery for long-term disease control in children and adolescents with ALK-positive inflammatory myofibroblastic tumors | en |
dc.type | Article | en |
dc.identifier.doi | 10.1200/PO.18.00297 | en |
dc.subject.keywords | clinical feature | en |
dc.subject.keywords | cohort analysis | en |
dc.subject.keywords | creatinine blood level | en |
dc.subject.keywords | critically ill patient | en |
dc.subject.keywords | drug dose reduction | en |
dc.subject.keywords | female | en |
dc.subject.keywords | follow up | en |
dc.subject.keywords | fracture | en |
dc.subject.keywords | gamma glutamyl transferase blood level | en |
dc.subject.keywords | hemoglobin blood level | en |
dc.subject.keywords | human | en |
dc.subject.keywords | infant | en |
dc.subject.keywords | leukocyte count | en |
dc.subject.keywords | lymph | en |
dc.subject.keywords | male | en |
dc.subject.keywords | maximum tolerated dose | en |
dc.subject.keywords | multiple cycle treatment | en |
dc.subject.keywords | neutropenia | en |
dc.subject.keywords | neutrophil | en |
dc.subject.keywords | outcome assessment | en |
dc.subject.keywords | overall survival | en |
dc.subject.keywords | plasma cell granuloma | en |
dc.subject.keywords | platelet count | en |
dc.subject.keywords | potassium blood level | en |
dc.subject.keywords | preschool child | en |
dc.subject.keywords | priority journal | en |
dc.subject.keywords | progression free survival | en |
dc.subject.keywords | pseudotumor | en |
dc.subject.keywords | retrospective study | en |
dc.subject.keywords | school child | en |
dc.subject.keywords | side effect | en |
dc.subject.keywords | treatment duration | en |
dc.subject.keywords | treatment response | en |
dc.subject.keywords | upper respiratory tract infection | en |
dc.subject.keywords | sodium blood level | en |
dc.subject.keywords | alanine aminotransferasealbumin | en |
dc.subject.keywords | alkaline phosphatase | en |
dc.subject.keywords | anaplastic lymphoma kinase | en |
dc.subject.keywords | aspartate aminotransferase | en |
dc.subject.keywords | bilirubin | en |
dc.subject.keywords | creatinine | en |
dc.subject.keywords | crizotinib | en |
dc.subject.keywords | gamma glutamyltransferase | en |
dc.subject.keywords | hemoglobin | en |
dc.subject.keywords | potassium | en |
dc.subject.keywords | sodium | en |
dc.subject.keywords | adolescent | en |
dc.subject.keywords | adolescent disease | en |
dc.subject.keywords | alanine aminotransferase blood level | en |
dc.subject.keywords | albumin blood level | en |
dc.subject.keywords | alkaline phosphatase blood level | en |
dc.subject.keywords | article | en |
dc.subject.keywords | aspartate aminotransferase blood level | en |
dc.subject.keywords | bilirubin blood level | en |
dc.subject.keywords | cancer control | en |
dc.subject.keywords | cancer recurrence | en |
dc.subject.keywords | cancer surgery | en |
dc.subject.keywords | cancer survival | en |
dc.subject.keywords | cellulitis | en |
dc.subject.keywords | child | en |
dc.subject.keywords | childhood cancer | en |
dc.subject.keywords | clinical article | en |
dc.relation.url | https://www.embase.com/search/results?subaction=viewrecord&id=L2002517474&from=exporthttp://dx.doi.org/10.1200/PO.18.00297 | | en |
dc.identifier.risid | 2311 | en |
dc.description.pages | 1-11 | en |
item.grantfulltext | none | - |
item.openairetype | Article | - |
item.fulltext | No Fulltext | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
Appears in Sites: | Children's Health Queensland Publications |
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.